Home Newsfeeds JMP Securities Maintains Market Outperform on Pardes Biosciences, Lowers Price Target to $5

JMP Securities Maintains Market Outperform on Pardes Biosciences, Lowers Price Target to $5

JMP Securities analyst Roy Buchanan maintains Pardes Biosciences (NASDAQ:PRDS) with a Market Outperform and lowers the price target from $9 to $5.

byBenzinga Newsdesk

March 15, 2023

1 minute read

JMP Securities analyst Roy Buchanan maintains Pardes Biosciences (NASDAQ:PRDS) with a Market Outperform and lowers the price target from $9 to $5.

Oculis Reveals Top Line Results From DIAMOND Stage 1 Phase 3 Trial In Diabetic Macular Edema With OCS-01 Eye Drops

By Benzinga Newsdesk

May 22, 6:36 AM

DIAMOND trial in Diabetic Macular Edema (DME) with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with robust statistical significance

OCS

Tilray’s RIFF Cannabis Brand Launches New THC Beverages

By Vuk Zdinjak

July 12, 8:42 AM

Cannabis lifestyle brand RIFF, from Tilray Brands, Inc. (NASDAQ: TLRY) (TSX:TLRY) debuts its new ready-to-drink, sparkling THC beverages with two flavors: Blue Raspberry Ice and Wild Raspberry Lemonade.

TLRY